BioMarin Pharmaceutical, Inc. (NASDAQ:BMRN)
The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
wishingwealth stock list Tue, Apr 23, 2013, 8 new high stocks w/good recent earnings and technicals TC2000 scan
Recs
You can dip your foot in the pool, but you can't have a swim
Recs
Since I bought this stock it has gone up 139% and keeps growing.
Recs
It has a niche position for research and development in rare ailments.
Recs
Tremendous pipeline of orphan drug candidates
Recs
The global target market for Morquio syndrome patients with ability to pay for treatment is around 2500 patients. ThinkEquity analyst Kimberly Lee estimates the market potential of GALNS at 575 million annually. This would be $230,000 annually per patient... It goes without saying that Kimberly's math skills are at a preschool level.
Recs
GALNS data coming up soon and the eternal buyout hype should keep it going up
Recs
porto.likedded it.
Recs
IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MED 7 89 EB NEG
Recs
Value of omega 3 fatty acids from ocean getting greater recognition. Efficient extraction process
Recs
Up Up and away
Recs
Good pipeline. Filling niches where big pharma isn't interested in going. Solid front office leadership
Recs
A Director resigned today because his industry contacts led him to find out the CEO hid from the Board a purchase offer. This is the size of company that many others could purchase in order to get its intellectual property.
Recs
i usually don't by based soley on a recommendation without researching it my self, but I did this one. probably a mistake?
Recs
Three approved drugs which are all classified as orphan drugs make this a slightly profitable company. Pipeline is a few years out so look for them to try to make a near term acquisition or be taken out themselves.
Recs
With the economy coming back and baby boomers getting older, this company should do very well.
Recs
Pharmaceutical companies should remain strong, even with a relatively high P/E I still like its chances in the next year.
Recs
A rising star following GENZ. Good deal with LJPC recently on lupus drug.
Recs
Has a good position in the market for drugs that can help people.
Recs
I own it and I'm scared to sell. They're bound to keep coming up with new drugs.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 108 : 1 2 3 4 5 6 Next »